AI Verdict
GMED has stronger fundamentals based on our AI analysis.
GNLX vs GMED Fundamental Comparison
| Metric | GNLX | GMED |
|---|---|---|
| Revenue | $8,000.0 | $2.9B |
| Net Income | $-32.1M | $537.9M |
| Net Margin | -401,812.5% | 18.3% |
| ROE | -278.5% | 11.8% |
| ROA | -168.9% | 10.1% |
| Current Ratio | 2.43x | 4.26x |
| Debt/Equity | 0.79x | 0.00x |
| EPS | $-0.86 | $3.92 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
GNLX vs GMED: Frequently Asked Questions
Is GNLX or GMED a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), GMED has stronger fundamentals. GNLX is rated STRONG SELL (88% confidence) while GMED is rated BUY (78% confidence). This is not investment advice.
How does GNLX compare to GMED fundamentally?
GENELUX Corp has ROE of -278.5% vs GLOBUS MEDICAL INC's 11.8%. Net margins are -401,812.5% vs 18.3% respectively.
Which stock pays higher dividends, GNLX or GMED?
GNLX has a dividend yield of N/A or no dividend while GMED has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in GNLX or GMED for long term?
For long-term investing, consider that GNLX has STRONG SELL rating with 88% confidence, while GMED has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about GNLX vs GMED?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For GNLX vs GMED, the AI consensus favors GMED based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.